1052714-46-1

Basic information

• Product Name: 6-Bromo-5-fluoro-2-pyridinecarboxylic acid
• Synonyms: 6-Bromo-5-fluoro-2-pyridinecarboxylic acid;6-BroMo-5-fluoropicolinic acid;2-Pyridinecarboxylic acid, 6-broMo-5-fluoro-
• CAS NO: 1052714-46-1
• Molecular Formula: C₆H₃BrFNO₂
• Molecular Weight: 219.9959232
• Mol File: 1052714-46-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 331.3 °C at 760 mmHg
• Flash Point: 154.2 °C
• Appearance: /
• Density: 1.903
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.19±0.10(Predicted)
• CAS DataBase Reference: 6-Bromo-5-fluoro-2-pyridinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-5-fluoro-2-pyridinecarboxylic acid(1052714-46-1)
• EPA Substance Registry System: 6-Bromo-5-fluoro-2-pyridinecarboxylic acid(1052714-46-1)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 1052714-46-1(Hazardous Substances Data)

Usage

General Description

6-Bromo-5-fluoro-2-pyridinecarboxylic acid is a chemical compound with the molecular formula C6H3BrFNO2. It is a derivative of pyridinecarboxylic acid and contains bromine and fluorine atoms attached to the pyridine ring. 6-Bromo-5-fluoro-2-pyridinecarboxylic acid is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceutical drugs. It has also been studied for its potential anti-cancer and anti-inflammatory properties. Additionally, it may have applications in the field of organic chemistry as a building block for the synthesis of more complex molecules.

InChI:InChI=1S/C6H3BrFNO2/c7-5-3(8)1-2-4(9-5)6(10)11/h1-2H,(H,10,11)

Upstream product

• 374633-36-0 2-bromo-3-fluoro-6-methylpyridine 

Downstream Products

• 1210418-85-1 6-(3,4-difluorophenyl)-5-fiuoropicolinic acid 
• 1210418-75-9 6-(2,3-difluorophenyl)-5-fiuoropicolinic acid 
• 1210418-84-0 5-fluoro-6-(2-fluorophenyl)picolinic acid 
• 1210418-87-3 6-(2,4-difluorophenyl)-5-fiuoropicolinic acid 
• 1210418-86-2 (2,5-difluorophenyl)-5-fluoropicolinic acid 
• 1210419-26-3 methyl 6-bromo-5-fluoropyridine-2-carboxylate 
• 1214337-05-9 6-chloro-5-fluoro-2-picolinic acid methyl ester 
• 1227605-60-8 6-bromo-5-fluoropyridine-2-carbaldehyde 
• 1355011-31-2 methyl 6-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-2,6-difluorophenyl)-5-fluoropicolinate 
• 1355011-30-1 methyl 6-(2,6-difluoro-4-hydroxyphenyl)-5-fluoropyridine-2-carboxylate 
• 1395282-15-1 methyl 6-(2,6-difluoro-4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-5-fluoropicolinate 
• 1355011-39-0 methyl 6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxylate 
• 1586040-62-1 N-(5-((2S,5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-5-fluoro-6-(2-fluoro-4-methoxyphenyl)picolinamide 

Relevant articles and documents

Oxazolyl pyrimidinone amide compound or medicinal salt thereof, preparation method and application of oxazolyl pyrimidinone amide compound or medicinal salt thereof

The invention discloses an oxazole pyrimidone amide compound or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. The oxazole pyrimidone amide compound has the following structural general formula (I) shown in the description, wherein R1 and R2 are respectively and independently selected from hydrogen and C1-3 alkyl, R3 is selected from C1-3 alkyl groups, R4 and R5 are independently selected from 5-6-membered aryl groups, the aryl groups are phenyl groups or heteroaryl groups containing 1-3 heteroatoms, the heteroatoms are selected from oxygen atoms or nitrogen atoms, and the heteroatoms are located at any position on the heteroaryl groups; the aryl is unsubstituted or at least substituted by one or more halogens or C1-3 alkyl groups, C1-3 polyhalogenated alkyl groups and C1-3 alkoxy groups. The invention also discloses an application of the compound as a TRPA1 antagonist, and the compound is used for preparing medicines for treating or preventing diseases, symptoms and/or obstacles regulated by TRPA1, such as pain and the like.

N-(3-PYRIDYL) BIARYLAMIDES AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.

CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof, as further described herein. Also provided are formulations comprising compounds of formula I, and a method to use such compounds for treating a disease or condition mediated by Provirus Integration of Maloney Maloney Kinase (PIM Kinase), GSK3, PKC, KDR, PDGFRa, FGFR3, FLT3, or cABL.